Payment overview · 2025
General Payments
$150.94
8 reported records · 4 companies
Healthcare provider profile · identity verified
Brian D Phipps, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · COLUMBUS, OH · NPI 1710085287
Verified facts
What the public records show
CMS Open Payments records show Brian D Phipps, M.D. received $150.94 in general payments during 2025 across 8 reported records.
Novo Nordisk Inc accounted for 49.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Shingrix, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $74.74 | 49.5% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $35.99 | 23.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.34 | 13.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.87 | 13.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $150.94 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $58.56 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $58.56 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.34 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.34 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.87 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.74 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.25 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 128 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 120 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 35 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 60 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
35 | 31 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
60 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
120 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
128 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
25 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 789 | 225 |
| Lisinopril | Lisinopril | 483 | 131 |
| Amlodipine Besylate | Amlodipine Besylate | 437 | 124 |
| Levothyroxine Sodium | Levothyroxine Sodium | 358 | 95 |
| Tamsulosin Hcl | Tamsulosin Hcl | 297 | 87 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 294 | 89 |
| Losartan Potassium | Losartan Potassium | 281 | 75 |
| Simvastatin | Simvastatin | 278 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 268 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 237 | 78 |
| Omeprazole | Omeprazole | 218 | 64 |
| Gabapentin | Gabapentin | 200 | 50 |
| Trazodone Hcl | Trazodone Hcl | 185 | 50 |
| Furosemide | Furosemide | 181 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 172 | 50 |
| Metformin Hcl Er | Metformin Hcl | 161 | 50 |
| Metformin Hcl | Metformin Hcl | 153 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 145 | 42 |
| Eliquis | Apixaban | 128 | 31 |
| Montelukast Sodium | Montelukast Sodium | 125 | 37 |
| Tramadol Hcl | Tramadol Hcl | 122 | 27 |
| Potassium Chloride | Potassium Chloride | 121 | 37 |
| Ozempic | Semaglutide | 120 | 19 |
| Meloxicam | Meloxicam | 112 | 34 |
| Sertraline Hcl | Sertraline Hcl | 108 | 27 |
| Allopurinol | Allopurinol | 103 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 103 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 102 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 102 | 29 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 101 | 28 |
| Alprazolam | Alprazolam | 96 | 24 |
| Synthroid | Levothyroxine Sodium | 93 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 91 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 87 | 23 |
| Carvedilol | Carvedilol | 86 | 28 |
| Ezetimibe | Ezetimibe | 83 | 24 |
| Atenolol | Atenolol | 82 | 22 |
| Xarelto | Rivaroxaban | 79 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 77 | 24 |
| Valsartan | Valsartan | 75 | 22 |
| Finasteride | Finasteride | 74 | 21 |
| Buspirone Hcl | Buspirone Hcl | 73 | 23 |
| Azithromycin | Azithromycin | 72 | 62 |
| Fenofibrate | Fenofibrate | 71 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 60 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 57 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 52 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 51 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | 16 |
| Methylprednisolone | Methylprednisolone | 50 | 39 |
| Oxycodone Hcl | Oxycodone Hcl | 50 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 50 | 16 |
| Bupropion Xl | Bupropion Hcl | 49 | 16 |
| Clonazepam | Clonazepam | 47 | suppressed |
| Prednisone | Prednisone | 46 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | 12 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 42 | 42 |
| Benazepril Hcl | Benazepril Hcl | 42 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 42 | 12 |
| Memantine Hcl | Memantine Hcl | 42 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 39 | 11 |
| Donepezil Hcl | Donepezil Hcl | 39 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 39 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | 11 |
| Mirtazapine | Mirtazapine | 38 | suppressed |
| Telmisartan | Telmisartan | 36 | suppressed |
| Diazepam | Diazepam | 35 | suppressed |
| Glimepiride | Glimepiride | 35 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 35 | 12 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 35 | 31 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 34 | 11 |
| Clonidine Hcl | Clonidine Hcl | 34 | 12 |
| Famotidine | Famotidine | 34 | 11 |
| Klor-Con M20 | Potassium Chloride | 34 | 12 |
| Warfarin Sodium | Warfarin Sodium | 34 | 13 |
| Pregabalin | Pregabalin | 33 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Cefdinir | Cefdinir | 30 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 11 |
| Temazepam | Temazepam | 30 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 30 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 29 | suppressed |
| Amoxicillin | Amoxicillin | 28 | 24 |
| Jantoven | Warfarin Sodium | 28 | suppressed |
| Linzess | Linaclotide | 28 | suppressed |
| Celecoxib | Celecoxib | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Testosterone | Testosterone | 26 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 23 |
| Dilt-Xr | Diltiazem Hcl | 24 | suppressed |
| Dutasteride | Dutasteride | 24 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 19 |
| Labetalol Hcl | Labetalol Hcl | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 17 |
| Trulicity | Dulaglutide | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Premarin | Estrogens, Conjugated | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 16 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 13 |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | 12 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Budesonide Ec | Budesonide | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $150.94 · 8 records | Novo Nordisk Inc | AIRSUPRA, ELIQUIS, NURTEC ODT, Ozempic, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, Wegovy | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error